Special Issue

Non-antimicrobial Agents as Adjuvants against Bacterial Infections

Message from the Guest Editors

The slow development of new antibiotics together with the rapid development of resistance sometimes makes it difficult to resolve bacterial infections. Therefore, there is an urgent necessity to find new treatment alternatives for bacterial infections. In this context, non-antimicrobial approaches (immunotherapy, phage therapy, inhibitors of bacterial virulence factors, etc.) as adjuvants to antimicrobial agents have been proven as treatment alternatives against these kinds of infections. This Special Issue seeks manuscript submissions on all aspects of non-antimicrobial approaches as adjuvants to antimicrobials. All manuscripts that increase scientific knowledge about the use of non-antimicrobial approaches as adjuvants to antimicrobials, either experimental or pre-clinical, including in vitro studies, experimentation on animal models, and combinations used in routine clinical practice, are welcome.

Guest Editors

Dr. María E. Pachón-Ibáñez

Dr. Clara Ballesté-Delpierre

Prof. Dr. Maria Tomas

Deadline for manuscript submissions

closed (31 December 2021)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/68178

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI